Global Apheresis Market Surge Valuation US$4.33 bn by the end of 2025


Transparency Market Research (TMR) observes in a research report that the competitive landscape in the global apheresis market is likely to be intense owing to the fact that a few leading vendors hold a substantial share in the market. The future threat arising from new entrants is likely to be comparatively low over the coming years because of the license required for manufacturing equipment, technical expertise needed to venture into this field, and expensive nature of the manufacturing process, which is keeping the new players at bay.

The focus on mergers, collaborations, and strategic collaborations is likely to be high in the coming years with leading companies looking forward to tighten their grip in the intensely competitive market and amid the growing cost related pressures. The leading companies in the market comprise B. Braun Melsungen AG, Cerus Corporation, Fresenius Kabi AG, Haemonetics Corporation, Terumo Corporation, and Asahi Kasei Medical Co. Ltd.

According to a TMR analyst, “The global market for apheresis is anticipated to exhibit a 10.2% CAGR between 2017 and 2025. In 2016, the market was worth US$1.85 bn and is likely to touch a valuation of US$4.33 bn by the end of 2025.” Based on procedure, the market has been segmented into erythrocytapheresis, leukapheresis, plateletpheresis, LDL apheresis, photopheresis, and plasmapheresis. Among all these, the market was reigned by the plasmapheresis segment in 2016 owing to the growing number of procedures pertaining to donor plasmapheresis across the globe. The segment is further estimated to experience an 8.9% CAGR over the course of the forecast period. Region-wise, the market is anticipated to be dominated by North America until the end of the forecast period. This growth can be attributed to the extensive development of the healthcare infrastructure in the region.

The market is additionally anticipated to profit by the enlarging set of therapeutic apheresis, which is provoking the expanded utilization of apheresis methodology in the treatment of various ailments and signs. According to the American Society for Apheresis’ (ASFA) Apheresis rule’s 2016 version, there are 87 ailments (78 out of 2013 release) and 179 sign for apheresis. In 2016, three new hematological signs were included these rules. Such enlarging utilizations of apheresis is anticipated to drive development for apheresis market in the coming years.

The set-up of apheresis includes expensive disposables and apheresis systems. Furthermore, technically skilled operators are needed to conduct these procedures. This further, raises the cost of the operations, thus, making the complete procedure expensive. This type of situation also becomes a Herculean state in developing economies. Apheresis is also termed unaffordable for treating certain other diseases in which several other alternatives are also available which are equally efficient in treating the disease and are inexpensive as well. This issue is anticipated to have a huge impact on the growth of the global market for apheresis.

Request Sample Report@

Leave a Reply